Jianru Xiao

Prof. Jianru Xiao


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Biomaterials
Verified
Journal Article
Closed access
XWXinyu Wang
Xinyu Wang
JZJishen Zhang
Jishen Zhang
YWYitong Wang
Yitong Wang
CWChangping Wang
Changping Wang
JXJianru Xiao
Jianru Xiao
YCYiyun Cheng
Yiyun Cheng

21 June 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XWXinyu Wang
Xinyu Wang
XCXiaopan Cai
Xiaopan Cai
JHJingjing Hu
Jingjing Hu
NSNaimin Shao
Naimin Shao
FWFei Wang
Fei Wang
YCYiyun Cheng
Yiyun Cheng

10 February 2017 in Oncotarget
Verified
Journal Article
Open access
XCXin-Gang Cui
Xin-Gang Cui
ZHZhi-Tao Han
Zhi-Tao Han
SHShao-Hui He
Shao-Hui He
XWXing-Da Wu
Xing-Da Wu
TCTian-Rui Chen
Tian-Rui Chen
JXJianru Xiao
Jianru Xiao
HIF1/2 mediates hypoxia-induced LDHA expression in human pancreatic cancer cells

1 January 2021 in Biomaterials
Verified
Journal Article
Closed access
XGXin Gao
Xin Gao
LLLin Li
Lin Li
XCXiaopan Cai
Xiaopan Cai
QHQuan Huang
Quan Huang
JXJianru Xiao
Jianru Xiao
YCYiyun Cheng
Yiyun Cheng

17 January 2018 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
WCWei-Luo Cai
Wei-Luo Cai
WHWen-Ding Huang
Wen-Ding Huang
BLBo Li
Bo Li
TCTian-Rui Chen
Tian-Rui Chen
ZLZhen-Xi Li
Zhen-Xi Li
JXJianru Xiao
Jianru Xiao
Most patients with breast cancer in advanced stages of the disease suffer from bone metastases which lead to fractures and nerve compression syndromes. microRNA dysregulation is an important event in the metastases of breast cancer to bone. microRNA-124 (miR-124) has been proved to inhibit cancer progression, whereas its effect on bone metastases of breast cancer has not been reported. Therefore, this study aimed to investigate the role and underlying mechanism of miR-124 in bone metastases of breast cancer. In situ hybridization (ISH) was used to detect the expression of miR-124 in breast cancer tissues and bone metastatic tissues. Ventricle injection model was constructed to explore the effect of miR-124 on bone metastasis in vivo. The function of cancer cell derived miR-124 in the differentiation of osteoclast progenitor cells was verified in vitro. Dual-luciferase reporter assay was conducted to confirm Interleukin-11 (IL-11) as a miR-124 target. The involvement of miR-124/IL-11 in the prognosis of breast cancer patients with bone metastasis was determined by Kaplan-Meier analysis. Herein, we found that miR-124 was significantly reduced in metastatic bone tissues from breast cancers. Down-regulation of miR-124 was associated with aggressive clinical characteristics and shorter bone metastasis-free survival and overall survival. Restoration of miR-124 suppressed, while inhibition of miR-124 promoted the bone metastasis of breast cancer cells in vivo. At the cellular level, gain of function and loss-of function assays indicated that cancer cell-derived miR-124 inhibited the survival and differentiation of osteoclast progenitor cells. At the molecular level, we demonstrated that IL-11 partially mediated osteoclastogenesis suppression by miR-124 using in vitro and in vivo assays. Furthermore, IL-11 levels were inversely correlated with miR-124, and up-regulation IL-11 in bone metastases was associated with a poor prognosis. Thus, the identification of a dysregulated miR-124/IL-11 axis helps elucidate mechanisms of breast cancer metastases to bone, uncovers new prognostic markers, and facilitates the development of novel therapeutic targets to treat and even prevent bone metastases of breast cancer.

10 April 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
SWShu Wang
Shu Wang
DZDan Zhang
Dan Zhang
JHJinsheng Hu
Jinsheng Hu
QJQi Jia
Qi Jia
WXWei Xu
Wei Xu
JXJianru Xiao
Jianru Xiao
Bingpian is a time‐honored herb in traditional Chinese medicine (TCM). It is an almost pure chemical with a chemical composition of (+)‐borneol and has been historically used as a topical analgesic for millennia. However, the clinical efficacy of topical borneol lacks stringent evidence‐based clinical studies and verifiable scientific mechanism. We examined the analgesic efficacy of topical borneol in a randomized, double‐blind, placebo‐controlled clinical study involving 122 patients with postoperative pain. Topical application of borneol led to significantly greater pain relief than placebo did. Using mouse models of pain, we identified the TRPM8 channel as a molecular target of borneol and showed that topical borneol‐induced analgesia was almost exclusively mediated by TRPM8, and involved a downstream glutamatergic mechanism in the spinal cord. Investigation of the actions of topical borneol and menthol revealed mechanistic differences between borneol‐ and menthol‐induced analgesia and indicated that borneol exhibits advantages over menthol as a topical analgesic. Our work demonstrates that borneol, which is currently approved by the US FDA to be used only as a flavoring substance or adjuvant in food, is an effective topical pain reliever in humans and reveals a key part of the molecular mechanism underlying its analgesic effect.